59866-71-6

Basic information

• Product Name: N2-(1-oxohexadecyl)-L-lysine
• Synonyms: N2-(1-oxohexadecyl)-L-lysine;alpha(N)-Palmitoy-L-lysine;Einecs 261-964-8;L-Lysine, N2-(1-oxohexadecyl)-
• CAS NO: 59866-71-6
• Molecular Formula: C₂₂H₄₄N₂O₃
• Molecular Weight: 384.59636
• EINECS: 261-964-8
• Mol File: 59866-71-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 567.6°C at 760 mmHg
• Flash Point: 297.1°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 2.28E-14mmHg at 25°C
• Refractive Index: 1.48
• CAS DataBase Reference: N2-(1-oxohexadecyl)-L-lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N2-(1-oxohexadecyl)-L-lysine(59866-71-6)
• EPA Substance Registry System: N2-(1-oxohexadecyl)-L-lysine(59866-71-6)

Safety Data

• Hazardous Substances Data: 59866-71-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C22H44N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-21(25)24-20(22(26)27)17-15-16-19-23/h20H,2-19,23H2,1H3,(H,24,25)(H,26,27)/t20-/m0/s1

Upstream product

• 76315-00-9 N_α-palmitoyl-N_ε-benzyloxycarbonyl-L-lysine 
• 16079-52-0 sodium salt of L-lysine 
• 112-67-4 n-hexadecanoyl chloride 
• 14464-31-4 palmitic acid N-succinimide ester 
• 57-10-3 1-hexadecylcarboxylic acid 
• 2418-95-3 (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Disclosed herein are compounds including a single-stranded oligonucleotide (A) having a nucleobase sequence complementary to a portion of the dystrophin pre-mRNA, their preparation, and uses thereof for the treatment of Duchenne muscular dystrophy.

LIPID-MODIFIED NUCLEIC ACID COMPOUNDS AND METHODS

Disclosed herein, inter alia, are lipid-modified nucleic acid compounds of the following structure, their preparation, and their use: (I).

Purification method of N-2-palmitoyl-N-6-fluorenylmethoxycarbonyl-L-lysine

The invention relates to a purification method of an N-2-palmitoyl-N-6-fluorenylmethoxycarbonyl-L-lysine (hereinafter referred to as a compound 1). According to the purification method, raw materialswith the content of the compound 1 being less than 98.5 percent are treated through three purification manners including a salt formation extraction method, a recrystallization method and a dissolvingand filtering method or any combination of the three purification manners to finally obtain the compound 1 with the content being equal to or greater than 98.5 percent.